CURRICULUM VITAE
Name: Neslihan Cabıoğlu 29.11./2022
Citizenship: Turkish
Place of Birth: Istanbul
Work Address: Istanbul University, Istanbul Faculty of Medicine
Department of Surgery, Millet cad. Çapa, Fatih
Istanbul, Turkey
Telephone: (212) 5340210
Fax: (212) 5340210
Email: neslicab@yahoo.com
EDUCATION
Residency: Istanbul University, Istanbul Faculty of Medicine, Department of General Surgery, Istanbul, Turkey (2000)
Medical Education: Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
(1994)
Licence: Istanbul University, Department of Immunology, Istanbul , Turkey (2001)
Postdoctoral Research Fellowship: Postdoctoral Research Fellow: Departments of Surgical Oncology and Cancer Biology, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA; September 2001-January 2005
Health Ministry Haseki Research and Training Hospital, Istanbul; 2001; 2005-2007; 2008-2010
Istanbul University, Istanbul Faculty of Medicine, Department of General Surgery (2007-2008)
Associate Professor (2009)
Acıbadem University, School of Medicine (2010-2013)
Istanbul University, Istanbul Faculty of Medicine, Department of General Surgery (2013-present)
Professor of Surgery (2016)
Observerships/Fellowships:
Royal Liverpool University, Department of Immunology, Liverpool, İngiltere, 1992 July-August.
Ludwig Maximilian University (Grosshadern) Obstetric and Gynecology, Munich, Germany, 1993 July-August.
South Manchester University Hospital Breast Clinic, Manchester, UK (September 2001),“Astra Zeneca Breast Cancer Clinical Grant”
Postdoctoral Research Fellow: Departments of Surgical Oncology and Cancer Biology, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA; September 2001-January 2004
Department of Breast Pathology, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA; February 2004-January 2005
The University of Pittsburg-Department of Surgery and Combined Breast Program of UPMC/Magee-Womens Hospital, 2 May-6 May 2011.
2-14 June 2014 and May-June 2016; European Academy Of Senology, under Dr Mahdi Rezai’s supervision; Düsseldorf, Germany.
Scientific Awards:
1988: 3rd degree from Istanbul High School
1988: “Deutsches Academisches Austauschdienst” Grant
1999/2000: Istanbul University Faculty of Medicine, Research Foundation, “Succesfull Research Fellow Certificate’.
29th April 2004: ASCO Foundation Merit Award.
Memberships
The American Society of Breast Surgeons
Turkish Surgical Society
Turkish Breast Diseases Federation
İstanbul MEMEDER (Breast Health Society, anonprofit non-government society; Executive Member)
SENATURK
Turkish Immunology Society
Breast Health Working Group
CURRENT AFFILIATIONS
Department of General Surgery, Istanbul University, Istanbul Faculty of Medicine (since November 2013)
Millet cad, Capa, Fatih, Istanbul 34390
Istanbul, Turkey
APPOINTMENTS
Acıbadem University, School of Medicine, Dep. General Surgery
Co-Leader, Medical School Education Program, Associate Professor of Surgery (2011-2013)
Istanbul University, Istanbul Faculty of Medicine, Erasmus Co-Coordinator, 2018-present
EXAMINATIONS PASSED
Examination Commission for Foreign Medical Graduates
CSA
Associate Professorship
European Board of Breast Surgery (FEBS)
PUBLICATIONS
BOOK CHAPTERS
1. Kuerer, H.M. and Cabioglu N. “Nipple discharge and ductal secretions”, Advanced Therapy of Breast Diseases, second edition, ed. E.S. Singletary and G.L. Robb and G.N. Hortobagyi, 37-43, BC Decker Inc, 2004.
2. N Cabioglu, Kuerer, H.M. “Nipple discharge and ductal secretions”, Advanced Therapy of Breast Diseases, third edition, eds. G.V. Babiera, and R.J.Skoracki, and F.J. Esteva 311-337, People’s Medical Publishing House, Shelton, Connecticut, USA, 2012.
3. Deniz Eren-Böler, Neslihan Cabioğlu. Evaluation of Patients for Metastases Prior to Primary Therapy. In: Adnan Aydıner, Abdullah İğci, Atilla Soran, eds. Breast Disease Volume II: Management and Therapies. Springer, 2016:13-25
4. Neslihan Cabioğlu. Staging of Breast Cancer. In: Adnan Aydıner, Abdullah İğci, Atilla Soran, eds. Breast Disease Volume II: Management and Therapies. Springer, 2016:25-45
5. Neslihan Cabioğlu, Enver Özkurt, Ayfer Kamalı Polat. Local-Regional Recurrence after Breast-Conservation Treatment or Mastectomy. In: Adnan Aydıner, Abdullah İğci, Atilla Soran, eds. Breast Disease Volume II: Management and Therapies. Springer, 2016:465-489.
6. Neslihan Cabioglu, Bahadır Güllüoglu. Role of Surgery on the Primary Cancer of the De Novo Stage IV Disease. Breast Exam Guide.(2022)
PUBLICATIONS
1. Cabioglu, N., Taviloglu K, Guloglu R, Gunay K, Akinci O. “Dual Effect of An Intravenous Immunoglobulin-G Trial in a Patient with Severe Streptococcal Necrotizing Fasciitis’ Sepsis: A Case Report,” Eur. J. Surg. Crit. Care, 22, 191-193 (1999).
2. Bilir A., Ozmen V, Cabioglu N, et al. “Dimethyl sulfoxide increases the antitumor cytotoxicities of 5-fluorouracil and adriamycin on FMA-3 cell line cultures in tumor colony-forming assays,” International Congress on Senology Breast Diseases, editor: J.Cardoso da Silva, 605-611, 1998.
3. Yazici H, Bitisik O, Akisik E, N. Cabioglu, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis I, Dalay N, Ozcelik H. “BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients,” Br J Cancer 2000; 83, 737-42.
4. Ozmen, V., Cabioglu N, Dolay K, et al. “Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: TLI is a powerful independent prognostic factor,” Breast Cancer Res. Treat., 68: 147-157 (2001).
5. Gunay K, Cabioglu N, Barbaros U, Taviloglu K, Ertekin C. Endoscopic ligation for patients with active bleeding Mallory-Weiss tears. Surg Endosc. 2001 Nov;15(11):1305-7.
6. Dolay K, Akçakaya A, Soybir G, N Cabioglu, Müslümanoğlu M, Iğci A, Topuzlu C. Endoscopic sphincterotomy in the management of postoperative biliary fistula A complication of hepatic hydatid disease.Surg Endosc. 2002; 16(6):985-8.
7. Cabioglu, N, S. Bilgic, G. Deniz, E. Aktas, B. Kiran, A.Turna, K. Gunay, F. Esen, “Decreased Cytokine Expression in Peripheral Blood Lymphocytes of Patients with Severe Sepsis,” Arch. Surg 2002; 137, 1037-43.
8. Cabioglu, N, A. Igci, E. Aktas, E.O. Yildirim, S. Bilgic, M. Muslumanoglu, Y. Bozfakioglu, M. Kecer, V. Ozmen, G. Deniz, “An ultrasensitive tumor enriched flow-cytometric assay for detection of isolated tumor cells in bone marrow of patients with breast cancer,” Am. J. Surg 2002; 184, 414-7.
9. Ozmen, V, M. Muslumanoglu, N. Cabioglu, S. Tuzlali, R. Ilhan, A. Igci, M. Kecer, Y. Bozfakioglu, T. Dagoglu, “Increased false negative rates in sentinel lymph node biopsies in patients with multifocal breast cancer,” Breast Cancer Res. Treat, 76, 237-244 (2002).
10. Ozmen, V., N. Cabioglu, A. Igci, , A. Aydiner, M. Dincer, T. Dagoglu, A. Bilir, M. Muslumanoglu, Y. Bozfakioglu, E.Topuz, “Inflammatory breast cancer: preliminary results of anthracycline-based neoadjuvant chemotherapy,” Breast J., 9, 79-85 (2003).
11. Cabioglu, N., K.K. Hunt, S.E. Singletary, T.W. Stephens, S. Marcy, F. Meric, M.I. Ross, G.V. Babiera, F.C. Ames, H.M. Kuerer, “Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge,” J. Am. Coll. Surg., 196, 354-364 (2003).
12. Cabioglu, N., S. Krishnamurthy, H.M.Kuerer, K.K.Hunt, S.E. Singletary, F. Meric-Bernstam, M.I. Ross, B.W. Feig, F.C. Ames, G.V. Babiera, “Feasibility of breast-conserving surgery in patients with breast cancer associated with nipple discharge,” Cancer, 101, 508-517 (2004).
13. Cabioglu N., K.K. Hunt, T.A. Buchholz, N. Mirza, S.E. Singletary, H.M. Kuerer, G.V. Babiera, F.C. Ames, A.A. Sahin, F. Meric-Bernstam, “Improving local control with breast-conserving therapy: a 27-year single-institution experience”, Cancer, 104, 20-29 (2005).
14. Cabioglu, N., J. Summy, C. Miller, N. Parikh, A. Sahin, S. Tuzlali, K. Pumiglia, G.E. Gallick, J.E. Price, “CXCL-12/stromal cell-derived factor-1 alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation,” Cancer Res 2005., 65, (6493-6497).
15. Cabioglu, N., M.S. Yazici, B. Arun, K.R. Broglio, G.N. Hortobagyi, J.E. Price, A.A. Sahin, “CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer,” Clin Cancer Res 2005; 11, 5686-93.
16. Cabioglu, N., A. Sahin, M. Doucet, E. Yavuz, A. Igci, E.O. Yildirim, E. Aktas, S. Bilgic, B. Kiran, G. Deniz, J.E. Price, “Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow” Clin Exp Metastasis., 22, 39-46 (2005).
17. Ozmen V, Karanlik H, Cabioglu, N et al. “Factors predicting the sentinel and non-sentinel node metastates in breast cancer,” Breast Cancer Res Treat., 95, 1-6 (2005).
18. Yumuk, PF, Aydiner A, Topuz E, Cabioglu N, Dogan O. “T-cell lymphoblastic lymphoma presenting with a breast mass,” Leuk. Lymphoma., 45, 833-836 (2004).
19. Bilir A., Ozmen V, M. Kecer, Eralp Y, Cabioglu N, Agizhali B, Camlica H, Aydiner A, “Thymidine labeling index: prognostic role in breast cancer,” Am. J. Clin. Oncol., 27, 40-46 (2004).
20. Asoglu, O., Ozmen V, Karanlik H, Tunaci M, Cabioglu N, Igci A, Selcuk UE, Kecer M, “Feasibility of surgical management in patients with granulamatous mastitis,” Breast J., 11, 108-114 (2005).
21. Taviloglu K., Cabioglu N, Cagatay A, et al, “Idiopathic Necrotizing fasciitis: risk factors and strategies for management”, Am Surgeon, 71, 315-320 (2005).
22. Yanar H, K. Taviloglu, C. Ertekin, R. Guloglu, U. Zorba, N. Cabioglu, I. Baspinar, “Fournier’s gangrene: risk factors and strategies for management,” World J Surg., 30, 1750-1754 (2006).
23. Ozmen V, Cabioglu N. “Sentinel node biopsy for breast cancer: current controversies (review),” Breast J., 12, S134-S142 (2006).
24. Sen-Oran E, V. Ozmen, A. Bilir, Cabioglu N, M. Muslumanoglu, A. Igci, N. Guney, M. Kecer, “Is the thymidine labeling index a good prognostic marker in breast cancer?,” World J Surg Oncol., 5, 93-97 (2007).
25. Ozmen V, O. Asoglu, H. Karanlik, N. Cabioglu, M. Kecer, H. Bakkaloglu, “Primary ovarian cancer presenting with axillary lymph node metastases: report of two cases,” Acta Chirur Belg 2007; 107, 75-7.
26. Andre F, Cabioglu N, H. Assi, J.C. Sabourin, S. Delaloge, A. Sahin, K. Broglio, C. Combadiere, C. Bucana, J.C. Soria, M. Cristofanilli, “Expression of Chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer,” Ann Oncol., 17, 945-951 (2006).
27. Cabioglu N., Hunt KK, Sahin AA, H.M. Kuerer, G. V. Babiera, S.E. Singletary, G.J. Whitman, M.I. Ross, F.C. Ames, B.W.. Feig, T.A. Buchholz, F. Meric-Bernstam, “Intraoperative Margin Assessment for Breast-conserving Surgery,” Ann Surg Oncol., 14, 1458-1471 (2007).
28. Cabioglu, N., Y. Gong, R. Islam, K.R. Broglio, N. Sneige, A. Sahin, A.M. Gonzalez-Angulo, P. Morandi, C. Bucana, G.N. Hortobagyi, M. Cristofanilli, “Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer,” Ann Oncol., 18, 1021-1029 (2007).
29. Ruffini PA, P. Morandi, N. Cabioglu, K. Altundag, M. Cristofanilli, “Manipulating the chemokine-chemokine receptor network to treat cancer,” Cancer., 109, 2392-2404 (2007).
30. Yip CH, Smith RA, Anderson BO, Miller AB, Thomas DB, Ang ES, Caffarella RS, Corbex M, Kreps GL, McTiernan A; Breast Health Global Initiative Early Detection Panel. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer. 2008 Oct 15;113(8 Suppl): 2244-56.
31. Ozmen V, Ozcinar B, Karanlik H, Cabioglu N, Tukenmez M, Disci R, Ozmen T, Igci A, Muslumanoglu M, Kecer M, Soran A. Breast cancer risk factors in Turkish women–a University Hospital based nested case control study. World J Surg Oncol. 2009, 7:1-8.
32. Cabioglu N, Ozmen V, Kaya H, Tuzlali S, Igci A, Muslumanoglu M, Kecer M, Dagoglu T. Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg. 2009; 208(1):67-74.
33. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol. 2009 Jun; 20(6):1013-9.
34. Boler DE, Uras C, Ince U, Cabioglu N. Factors predicting the non-sentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases. Breast. 2012; 21(4):518-23.
35. Gurdal SO, Karanlik H, Cabioglu N, Ozcinar B, Yavuz E, Tuzlali S, Ozmen V. Positive or close margins in breast conserving surgery: is re-excision always necessary? Eur J Surg Oncol. 2012; 38(5):399-406.
36. Gurdal SO, Kostanoglu A, Cavdar I, Ozbas A, Cabioglu N, Ozcinar B, Igci A, Muslumanoglu M, Ozmen V. Comparison of intermittent pneumatic compression with manual lymphatic drainage for treatment of breast cancer-related lymphedema. Lymphat Res Biol. 2012; 10(3):129-35..
37. Boler DE, Cabioglu N, Ince U, Esen G, Uras C.Sentinel Lymph Node Biopsy in Pure DCIS: Is It Necessary? ISRN Surg. 2012;2012: 394095.
38. Yasar KK, Pehlivanoglu F, Sengoz G, Cabioglu N. Successfully treated Mycobacterium abscessus mastitis: a rare cause of breast masses. Indian J Med Microbiol. 2011 Oct-Dec;29(4):425-7.
39. Ozmen V, Ozaydin A.N, Cabioglu N, Gulluoglu B.M., Unalan P.C, Gorpe S.,Oner B.R., Aribal E., Thomas DB, Anderson BO. Survey on a pilot mammographic screening program in Istanbul, Turkey. The Breast Journal, 2011; 17: 260-267.
40. Ozkan-Gurdal S, Cabioglu N, Ozcinar B, Muslumanoglu M, Ozmen V, Kecer M, Yavuz E, İgci A. Factors predicting microinvasion in Ductal Carcinoma in situ. Asian Pac. J Cancer Prev 2014: 15 (1): 56-60.
41. Kayhan A, Gurdal SO, Ozaydın N, Cabioglu N, Ozturk E, Ozcinar B, Aribal E, Ozmen V. Asian Pac. J Cancer Prev 2014: 15 (1): 1693-7.
42. Tukenmez M, Agcaoglu O, Aksakal N, Destek S, Cabioglu N, Barbaros U, Erbil Y, Bozbora A, Dinccag A, Ozmen V, Muslumanoglu M, Igci A. The use of Ligasure vessel sealing system in axillary dissection; effect on seroma formation. Chirurgia (Bucur); 2014 Sep-Oct; 109 (5); 620-5.
44. Karanlik H, Ozgur I, Cabioglu N et al. Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome. Eur J Surg Oncol. 2015 Sep;41(9):1226-33. doi: 10.1016/j.ejso.2015.06.003. Epub 2015 Jun 21.
45. Ozmen V, Atasoy A, Gokmen E, Ozdogan M, Guler N, Uras C, Ok E, Demircan O, Isıkdogan A, Cabioglu N, Sen F, Saip P. Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey. J Breast Health 2016 Jul 1;12(3):107-111. doi: 10.5152/tjbh.2016.2874. eCollection 2016 Jul.
46. Kayhan A, Aribal E, Sahin C, Can Taşcı O, Gürdal SO, Öztürk E, Hatipoğlu HH, Özaydın N, Cabioğlu, N Özçınar B, Özmen V. Radiologic findings of screen-detected cancers in an organized population-based screening mammography program in Turkey. Diagnostic Interventional Radology. 2016 Nov-Dec;22(6):508-513. doi: 10.5152/dir.2016.15250.
47. H Karanlik, I Ozgur, N Cabioglu et al. Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome. Eur J Surg Oncol. 2015 Sep;41(9):1226-33. doi: 10.1016/j.ejso.2015.06.003. Epub 2015 Jun 21.
48. Ozmen V, Atasoy A, Gokmen E, Ozdogan M, Guler N, Uras C, Ok E, Demircan O, Isıkdogan A, Cabioglu N, Sen F, Saip P. Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey. J Breast Health 2016 Jul 1;12(3):107-111. doi: 10.5152/tjbh.2016.2874. eCollection 2016 Jul.
49. Onder S, Fayda M, Karanlık H, Bayram A, Sen F, Cabioglu N, Tuzlal,, S, Ilhan R, Yavuz E. ..Loss of ARID1A expression is associated with poor prognosis in invasive micropapillary carcinomas of the breast: A clinicopathologic and immunohistochemical study with long-term survival analysis. Breast Journal 2017 Nov;23(6):638-646. doi: 10.1111/tbj.12823. Epub 2017 May 23
50. Ozmen V, Gurdal SO, Cabioglu N, et al. Cost-Effectiveness of Breast Cancer Screening in Turkey, a Developing Country: Results from Bahçeşehir Mammography Screening Project. Eur J Breast Health . 2017 Jul 1;13(3):117-122. doi: 10.5152/ejbh.2017.3528. eCollection 2017 Jul.
51. Cabioglu N, Karanlik H, Kandal D, et al. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2018 Oct;25(10):3030-3036.doi: 10.1245/s10434-018-6575-6. Epub 2018 Jul 5.
52. Soran A, Ozmen V, Ozbaş S, MF07 Study Group Members, Cabioglu N, et al. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01 Ann Surg Oncol. 2018 Oct;25(11):3141-3149. doi: 10.1245/s10434-018-6494-6. Epub 2018 May 17.Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.
53. Ozmen V, Gurdal SO, Cabioglu N, et al. Cost-Effectiveness of Breast Cancer Screening in Turkey, a Developing Country: Results from Bahçeşehir Mammography Screening Project. 2017 Jul 1;13(3):117-122. doi: 10.5152/ejbh.2017.3528. eCollection 2017 Jul.
54. Özkurt E, Tükenmez M, Güven E, et al and Cabioglu N. Favorable Outcome with Close Margins in Patients Undergoing Nipple/Skin Sparing Mastectomy with Immediate Breast Reconstruction: 5-year Follow-up. Balkan Med J. . 2018 Jan 20;35(1):84-92. doi: 10.4274/balkanmedj.2017.0029. Epub 2017 Sep 29.
55. Ozkurt E, Yardımcı E, Tükenmez Ersoy YE, Yilmaz R, Cabioğlu N et al. Intraoperative palpation of sentinel lymph nodes can accurately predict axilla in early breast cancer. Breast Journal . 2019 Jan;25(1):96-102. doi: 10.1111/tbj.13149. Epub 2018 Nov 12.
56. Özkurt E, Tükenmez M, Yılmaz R, Cabioğlu N, et al. Favorable Long-Term Outcome in Male Breast Cancer. Eur J Breast Health. 2018 Jul 1;14(3):180-185.. doi: 10.5152/ejbh.2018.3946. eCollection 2018 Jul.
57. Erdogan OS, Erciyaz SK, Bilir A, Tuncer ŞB, Odemiş DA, Kurul S, Karanlik H, Cabioglu N, Yazici H. Methylation Changes of Primary Tumors, Monolayer, and Spheroid Tissue Culture Environments in Malignant Melanoma and Breast Carcinoma. Biomed Res Int. 2019 Jan 17;2019:1407167.doi: 10.1155/2019/1407167. eCollection 2019.
58. Our 20-Year Institutional Experience with Surgical Approach for Breast Hamartomas. Türkyılmaz Z, Aydın T, Yılmaz R, et al and Cabioğlu N. Eur J Breast Health. 2019 Jul 1;15(3):171-175. doi: 10.5152/ejbh.2019.4624. eCollection 2019 Jul.
.
59. Cabioglu N, Onder S, Oner G, et al. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer. BMC Cancer. 2021 Apr 6;21(1):357. doi: 10.1186/s12885-021-08054-6.PMID: 33823818
60. Oner G, Önder S, Karatay H, …and Cabioğlu N. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. World J Surg Oncol 2021, . 2021 Sep 2;19(1):264.
61. Abbasov A, Çetin EA, Cabioglu N, et al. Differential Expression of Novel Immune Checkpoint Receptors on Tumor Infiltrating Lymphocytes in Patients with Locally Advanced Breast Cancer after Neoadjuvant Chemotherapy. Neoplasma. 2021 Sep;68(5):1079-1090. doi: 10.4149/neo_2021_210127N141. Epub 2021 Jun 7.
62. Bagbudar S, Karanlik H, Cabioglu N, et al. Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4, PD-1, and LAG-3. Appl Appl Immunohistochem Mol Morphol. 2022 Feb 1;30(2):99-107.
63. Cabioglu N, Karanlik H, Yildirim N., et al. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study. Eur J Surg Oncol, 2021; 47(10):2506-2514.
64. Simsek D, Emiroglu S, Yilmaz R, …, Cabioglu N. SPECT/CT Lymphoscintigraphy Guidance Simplifies and Improves Targeted Axillary Dissection of the Clipped Nodes After Neoadjuvant Chemotherapy in Initially Node-Positive Breast Cancer. Clin Nucl Med. 2022; 47(11):e682-e688
65. Ozkan-Gurdal S., Ozaydın N, Aribal E, Ozcinar B, Cabioglu N, Sahin C, Ozmen V. Bahcesehir long-term population-based screening compared to National Breast Cancer Registry Data: effectiveness of screening in an emerging country.Diagn Interv Radiol. 2021 Mar;27(2):157-163.doi: 10.5152/dir.2021.20486.
66. Cabioglu N, Gurdal SO, Kayhan A, et al. Poor Biological Factors and Prognosis of Interval Breast Cancers: Long-Term Results of Bahçeşehir (Istanbul) Breast Cancer Screening Project in Turkey
JCO Global Oncol . 2020 Jul;6:1103-1113. doi: 10.1200/GO.20.00145.
67. Gemici AA, Arıbal A, Özaydın N Gürdal SO, Özçınar B, Cabioğlu N, Özmen V. Comparison of Qualitative and Volumetric Assessments of Breast Density and Analyses of Breast Compression Parameters and Breast Volume of Women in Bahcesehir Mammography Screening Project. Eur J Breast Health2020 Apr 1;16(2):110-116.. doi: 10.5152/ejbh.2020.4943. eCollection 2020 Apr.
68. Uras C, Cabioglu N, Tokat F, Er O, Kara H, Korkmaz T, Bese N, Ince U. Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up. BMC Cancer 2022 Nov 25;22(1):1217.doi: 10.1186/s12885-022-10308-w.
69. Cabioglu N, Aktas EC, , Emiroglu S, Ozkurt E, Muslumanoglu M, Igci A, Ozmen V, Deniz G, Dinccag AS, Guven YI . Ozone therapy restores immune dysfunction in refractory idiopathic granulomatous mastitis as a novel potential therapeutic approach. Cell Biology Int . 2022 Nov 15. doi: 10.1002/cbin.11953. Online ahead of print.
70. Mollavelioglu B, Aktas EC, Cabioglu N, et al. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. World J Surg Oncol 2022 Oct 21;20(1):349. doi: 10.1186/s12957-022-02810-z.
71. Karanlik H, Cabioglu N, Oprea AL, et al. Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment Breast Care. 2021 Oct;16(5):468-474. doi: 10.1159/000512202. Epub 2020 Dec 16.
72. Soran A , Ozmen V, Ozbas S, and MF07-01 Study Group. Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial. 2021 Dec;233(6):742-751.e5. doi: 10.1016/j.jamcollsurg.2021.08.686. Epub 2021 Sep 13
73. Emiroglu S, Tukenmez M, Karakus S, Karanlik H, Onder S, Ozmen V, Cabioglu N, Ozkurt E, Yilmaz R, Muslumanoglu M. Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. Eur J Breast Health. 2022 Oct 1;18(4):353-359.doi: 10.4274/ejbh.galenos.2022.2022-8-1. eCollection 2022 Oct.
74. Yirgin IK, Engin G, Yildiz S, Aydın EC, Karanlık H Cabioglu N, Tukenmez M, Emiroglu S, S, Yildiz SO, Yavuz E, Saip P Aydiner A, Igci A Muslumanoglu M . Abbreviated and Standard Breast MRI in Neoadjuvant Chemotherapy Response Evaluation: A Comparative Study Current Med Imaging 2022;18(10):1052-1060.doi: 10.2174/1573405618666220223142009.
75. Yirgin IY, Koyluoglu O, Seker ME, Gurdal SO, Ozaydin AN, Ozcinar B, Cabioğlu N, Ozmen V, Aribal E. Diagnostic Performance of AI for Cancers Registered in A Mammography Screening Program: A Retrospective Analysis.Technol Cancer Res Treatment. 2022; 21:15330338221075172. doi: 10.1177/15330338221075172.
76. Soran A, Dogan L, Isık A, Ozbaş S, Trabulus DC, Demirci U, Karanlık H, Soyder A, Dag, A, Bilici A, Dogan M, Koksaş H, Sendur MAS, Gulcelik MA, Maralcan G, Cabioglu N, et al. The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study. Ann Surg Oncol,. 2021 Sep;28(9):5048-5057.doi: 10.1245/s10434-021-09621-8. Epub 2021 Feb 2.
77. Yirgin IK, Has Şimsek D, Arslan G, Cureoglu EA, Sari M, Onder S, , Şanlı Y, Cabiolgu N, Karanlık H, Tukenmez M, Dursun M, Muslumanoglu M, Ozmen V. . Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer. Eur J Radiol Open . 2020 Nov 19;7:100286. doi: 10.1016/j.ejro.2020.100286. eCollection 2020.
78. Soran A, Soyder A, Ozbas S, ….(MF07 Study Group Members), Cabioglu N, Uzunkoy A, Gulluoglu BM, Erdem E, Konca C, Sezgin E. The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q. Support Care Center. 2021 Jul;29(7):3823-3830. doi: 10.1007/s00520-020-05905-z. Epub 2020 Nov 26.
REVIEWER FOR SCI, SSCI, AHCI JOURNALS:
1) “The Breast”
2) “The European Journal of Surgical Oncology”
3) “Int J Cancer”
4) “Annals of Oncology”
5) Ann Surg Oncol
6) World J Surg Oncol
7) Eur J Breast Health
Associate Editor:
The Breast Journal (Hindawi)
Istanbul University Research Grants:
1. Biological factors in locally advanced breast cancer (PI). (1998)
2. The Prognostic and Therapeutic Importance of T-helper -1 Response in Severe Systemic Inflammatory Response and Severe Sepsis (Postdoctoral Fellow in Immunology, 1998)
3. Detection of bone marrow micrometastases in patients with early stage breast cancer by RT-PCR(1996).
4. Using an ultrasensitive tumor enriched by magnetic bead enriched flow-cytometric assay for detection of isolated tumor cells in bone marrow of patients with breast cancer (1997).
5. The predictive and prognostic importance of PD-L1 in patients receiving neoadjuvant chemotherapy (2017)
6. The prognostic importance of immune check point receptors and chemokine receptors in triple negative breast cancer (2017).
National and International Committees, Important Memberships
Turkish Surgical Society
Breast Health Working Group International
Turkish Federation of Breast Disease Societies (Manager of the Turkish Breast Cancer Big-Data)
Breast Health Society (MEMEDER, a non-governement social society)
Member of American Breast Surgeon’s Society
American College of Surgeons (applied for the official membership; invited and had a talk at the ACS Clinical Congress 2017 San Diego: N Cabioglu: (Breast cancer: National and International Disparities: Middle Eastern Perspective)
Ongoing Prospective Trials
1. Is Sentinel Lymph Node Biopsy With Radiotherapy Alone Without Axillary Lymph Node Dissection Safe Following Neoadjuvant Chemotherapy In Initially Clinically Axilla Positive Patients: Neosentiturk-Trial/Mf-18-03 (ClinicalTrials.gov: NCT04250129): Principal Investigator and Study Chair. presented as a poster at the 23rd Annual Meeting of the ASBrS in Las Vegas, April 6-10 2022 and in poster discussion in San Antanşo 2022: Axillary Recurrence Is Rare In Patients Undergoing Sentinel Lymph Node Biopsy Following Neoadjuvant Chemotherapy In Initially Clinically Node-Positive Breast Cancer: Early Results Of The Neosentiturk-Trial/Mf18-03.
2. EUBREAST-4: MELODY s
3. EUBREAST: AXANA-trial (collaborator)
4. Turkish Young Breast Registry (Principal Investigator)
5. Autoimmunity in Granulomatous mastitis
6. Intralesional Steroid Injection in Treatment of Granuolomatous Mastitis
